Comments on: Polymorphisms indicating risk of inflammatory bowel disease or antigenicity to anti-TNF drugs as biomarkers of response in children
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Book |
| Published: |
Elsevier,
2023-10-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_29237a28c7fb4acf97d7fc04e6eb47d0 | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Paula Zapata-Cobo |e author |
| 700 | 1 | 0 | |a Sara Salvador-Matín |e author |
| 700 | 1 | 0 | |a Marta Velasco |e author |
| 700 | 1 | 0 | |a Laura M. Palomino |e author |
| 700 | 1 | 0 | |a Susana Clemente |e author |
| 700 | 1 | 0 | |a Oscar Segarra |e author |
| 700 | 1 | 0 | |a Ana Moreno-Álvarez |e author |
| 700 | 1 | 0 | |a Ana Fernández-Lorenzo |e author |
| 700 | 1 | 0 | |a Begoña Pérez-Moneo |e author |
| 700 | 1 | 0 | |a Montse Montraveta |e author |
| 700 | 1 | 0 | |a Cesar Sánchez |e author |
| 700 | 1 | 0 | |a Mar Tolín |e author |
| 700 | 1 | 0 | |a Inés Loverdos |e author |
| 700 | 1 | 0 | |a María José Fobelo |e author |
| 700 | 1 | 0 | |a Victor Manuel Navas-López |e author |
| 700 | 1 | 0 | |a Lorena Magallares |e author |
| 700 | 1 | 0 | |a Ruth García-Romero |e author |
| 700 | 1 | 0 | |a José Germán Sánchez-Hernández |e author |
| 700 | 1 | 0 | |a Alejandro Rodríguez |e author |
| 700 | 1 | 0 | |a Ferrán Bossacoma |e author |
| 700 | 1 | 0 | |a María Jesús Balboa |e author |
| 700 | 1 | 0 | |a Enrique Salcedo |e author |
| 700 | 1 | 0 | |a María Sanjurjo-Sáez |e author |
| 700 | 1 | 0 | |a Luis A. López-Fernández |e author |
| 245 | 0 | 0 | |a Comments on: Polymorphisms indicating risk of inflammatory bowel disease or antigenicity to anti-TNF drugs as biomarkers of response in children |
| 260 | |b Elsevier, |c 2023-10-01T00:00:00Z. | ||
| 500 | |a 1096-1186 | ||
| 500 | |a 10.1016/j.phrs.2023.106938 | ||
| 546 | |a EN | ||
| 690 | |a Inflammatory bowel disease | ||
| 690 | |a Pharmacogenetics | ||
| 690 | |a Infliximab | ||
| 690 | |a Adalimumab | ||
| 690 | |a Polymorphism | ||
| 690 | |a Pediatric | ||
| 690 | |a Therapeutics. Pharmacology | ||
| 690 | |a RM1-950 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Pharmacological Research, Vol 196, Iss , Pp 106938- (2023) | |
| 787 | 0 | |n http://www.sciencedirect.com/science/article/pii/S1043661823002943 | |
| 787 | 0 | |n https://doaj.org/toc/1096-1186 | |
| 856 | 4 | 1 | |u https://doaj.org/article/29237a28c7fb4acf97d7fc04e6eb47d0 |z Connect to this object online. |